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Summary 
KSHV seroprevalence is very high in rural Uganda. Malaria infection and anaemia are the risk factors 
associated with KSHV seroprevalence and antibody levels in this study. These factors might cause 
reactivation of the virus and hence lead to increased transmission. 
 
Abstract 
We examined anaemia and malaria as risk factors for KSHV seropositivity and antibody levels in a 
long-standing rural Ugandan cohort, in which KSHV is prevalent. Samples from 4134 children, aged 
1-17 years, with a sex ratio of 1:1 and 3149 adults aged 18-103 years, 41% of whom were males, 
were analysed. Among children, malaria infection was associated with higher KSHV prevalence (61% 
versus 41% prevalence among malaria infected and uninfected respectively); malaria was not 
assessed in adults. Additionally, lower haemoglobin level was associated with an increased 
prevalence of KSHV seropositivity, both in children and in adults.  
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Introduction  
We recently reported KSHV prevalence of 95% among adults in a rural population cohort (the 
General Population Cohort (GPC) in Uganda [1], the highest prevalence of KSHV ever reported, in 
addition to high KSHV antibody levels. We propose that the very high prevalence in this population 
may be driven by frequent KSHV reactivation, viral shedding and transmission rates and that the 
high antibody levels also reflect frequent reactivation. It is important therefore to study potential co-
factors for reactivation in relation to KSHV prevalence and antibody levels. We have previously 
reported an association between malaria and hookworm infections and KSHV seropositivity in an 
urban population in Uganda [2, 3]. Since both malaria and hookworm are associated with anaemia, 
we hypothesized that anaemia may have a role in KSHV transmission via viral reactivation. This 
hypothesis is supported by data from in vitro experiments showing reactivation of KSHV in 
conditions of hypoxia [4]. In this study we aimed to confirm the high prevalence of KSHV in the GPC 
in recent years, with higher ART coverage, and determine the role of anaemia and malaria co-
infection as risk factors for KSHV prevalence and antibody levels in a highly endemic population.  
 
Methods 
Study population and socio-demographic data collection 
The General Population Cohort (GPC) is located in south-western Uganda in Kyamulibwa sub-
community of Kalungu district with an altitude of approximately 1200m above sea level. It is 
community-based open cohort of about 22,000 people in 25 adjacent villages [5]. This cross 
sectional study analysed plasma samples collected from two surveys, the adult survey and the 
children survey. The adults were surveyed in 2014/2015 and the children in 2016. Adults without 
haematological parameter data and children without either haematological parameter data or 
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malaria parasitaemia status data were excluded in the laboratory analysis. Children less than 1 year 
of age were excluded from the statistical analysis and children less than 2 years were not tested for 
HIV serostatus, due to the potential for maternal IgG to be present, which could affect antibody 
measurement. Socio-economic scores were generated for adults using Principal Component Analysis 
of various household indicators during the previous survey. 
 
Ethical approval 
The study was approved by the Research and Ethics Committee Uganda Virus Research Institute and 
the Uganda National Council for Science and Technology.  
 
Haematological and serological analysis 
During these two surveys, blood was collected from study participants and tested immediately after 
collection for HIV; a smaller proportion of samples were also tested for malaria parasitaemia and 
haemoglobin levels, using point-of care assays and rapid tests. HIV serostatus was determined using 
rapid diagnostic tests. Malaria parasitaemia was measured in children only, using malaria Rapid 
Diagnostic Tests (ONE STEP Malaria HRP-II (P.f) and pLDH (Pan) Antigen Rapid Test). Haemoglobin 
levels in g/dL were obtained from the Haemocue 201 analyzer.  
 
Stored plasma samples for both children and adults were retrieved and tested for KSHV antibodies 
using an in-house ELISA as previously described [6].  Samples from the two surveys were tested 
separately after simple randomisation onto ELISA plates. Antibodies to both K8.1 and ORF73 
proteins were measured as optical density. Each ELISA plate contained three negative and positive 
control wells; negative controls were used to calculate a cut-off value for every plate as previously 
described [2, 7]. Seropositivity was defined as reactivity to either K8.1 or ORF73 proteins. 
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Statistical analysis was carried out using STATA13 (Statacorp, College Station, Texas USA). ChildreŶ ?Ɛ
and ĂĚƵůƚƐ ? results were analysed separately. Haemoglobin levels were mean centred for easier 
interpretation. Anaemia was defined using haemoglobin levels in g/dL after altitude adjustment 
following WHO guidelines [8]. A constant value 0.5 was subtracted from haemoglobin levels for 
altitude adjustment, the results were then categorised into normal and anaemic using the following 
cut-off values: 11.0 for pregnant females and children below 5 years, 11.5 for children 5 to 11 years, 
12.0 for children 12 to 14 years and other females 15 years and above, 13.0 for males 15 years and 
above. These WHO haemoglobin reference ranges used to define anaemia may not be 
representative of African populations, as previously reported [9, 10], because they are based on 
western population data. We therefore analysed haemoglobin both as a continuous variable and as 
categorised into normal and anaemic using separate regression models. 
 
Linear regression with bootstrapped confidence intervals was used for antibody levels analysis, 
because they were severely skewed. Logistic regression was used for seroprevalence analysis, 
furthermore, we adjusted for clustering at the village level using survey commands. We assessed 
interaction between age and haemoglobin levels, as well as between age and anaemia in relation to 
anti-K8.1 antibody levels, anti-ORF73 antibody levels and KSHV prevalence based on a priori 
suspicions of interaction, using likelihood ratio tests.  
 
Results 
The characteristics of the individuals analysed are shown in supplementary Table 1. We analysed 
results from 3149 adults and 4134 children.  This analysis included children aged 1 to 17 years and 
adults aged 18 to 103 years (supplementary Table 1).  
 
Statistical analysis 
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KSHV prevalence was 91% in all adults (2871/3149) (supplementary Figure 1). Every 1g/dL decrease 
in haemoglobin values was associated with increased odds of being KSHV seropositive (OR=0.86 
(0.77, 0.96), P=0.006 and anaemic individuals were more likely to be KSHV seropositive compared to 
people with normal haemoglobin values, but this association was not statistically significant OR=1.25 
(0.87, 1.79), P=0.229 (Table 1A).  
 
We then analysed antibody levels to K8.1 and ORF73 proteins as continuous variables without 
categorising participants as seropositive or seronegative.  Anaemic adults had higher antibodies to 
ORF73 protein compared to individuals with normal haemoglobin values (coef. 0.28 (0.16, 0.39), 
P<0.0001. Similarly, every 1g/dL decrease in haemoglobin was associated with an increase in ORF73 
antibody ODs (Table 1B). The association between haemoglobin and antibodies to ORF73 protein 
was strongest among older people (Table 1C). Conversely, anti-K8.1 antibody levels were not 
significantly associated with either haemoglobin levels or anaemia (Table 1B). This might be 
attributed to the relative abundance of LANA compared to late lytic proteins such as K8.1, even 
during KS disease [11].   
 
Compared to HIV negative adults, HIV positive adults had lower antibodies to KSHV, especially those 
with CD4 counts of 500cell/PL or less (Table 1B). This may be due to B cell dysfunction caused by HIV 
infection, and consequent decreased antibody responses [12, 13]. On the other hand, HIV positive 
adults with CD4 counts above 500cells/PL, compared to HIV negative adults were more likely to be 
KSHV seropositive (Table 1A), which may be due to antiretroviral treatment. 
 
Risk factors for KSHV prevalence and antibody levels among children 
We then investigated associations between KSHV prevalence and antibody levels and risk factors 
among children. Overall, KSHV prevalence was 51% (2117/4134) in the children, the prevalence 
Risk factors for KSHV prevalence and antibody levels among adults  
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increased with age, rising from 31% among 1-5 year olds, to 53% among 6-12 year olds, to 73% 
among 13-17 year olds (supplementary Figure 1). We first adjusted for HIV status, age and sex, then 
malaria parasitaemia and anaemia/haemoglobin levels were added in the full models. In the first 
analysis, haemoglobin levels, malaria parasitaemia and age were strongly associated with KSHV 
prevalence (Table 2A). Every 1 g/dL decrease in haemoglobin levels increased the odds of being 
KSHV seropositive by 11% (P<0.0001) and the odds of being KSHV positive if anaemic compared to 
with normal haemoglobin levels was 1.42 (1.18, 1.71) (p<0.0001). The odds of being KSHV 
seropositive, if malaria infected, compared to the uninfected were 2.26 (1.85, 2.77) (P<0.0001) and 
every annual increase in age was associated with a 17% increased risk of being KSHV seropositive 
(Table 2A).  
 
After adjusting for malaria parasitaemia, the risk of being KSHV seropositive for every 1 g/dL 
decrease in haemoglobin reduced to 7% (p=0.005). Similarly, the odds of being KSHV seropositive in 
comparing anaemic individuals to people with normal haemoglobin levels reduced to 1.23 (1.01, 
1.49) p=0.037.  After adjusting for haemoglobin levels, the odds of being KSHV seropositive 
comparing people with and without malaria parasitaemia changed little (OR=2.12 (1.75, 2.57), 
p<0.0001) (Table 2A). Every annual increase in age remained strongly associated with increased 
KSHV prevalence risk, OR=1.18 (P<0.0001) even after adjusting for malaria parasitaemia and 
haemoglobin (Table 2A). 
 
We then finally investigated associations between the same risk factors and KSHV antibody levels 
(OD) as continuous variables without categorising participants as seropositive or seronegative. Only 
malaria parasitaemia was associated with both anti-K8.1 and anti-ORF73 antibody levels in the fully 
multivariate analysis (Table 2B).  
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Discussion  
We observed a significant association between haemoglobin levels and KSHV prevalence among 
children and adults, where people with low levels of haemoglobin were more likely to be KSHV 
seropositive. As a categorical variable, anaemia was associated with KSHV prevalence among 
children. Reduction in haemoglobin has been shown to cause hypoxia/low tissue oxygen, while 
hypoxia has been shown to reactivate KSHV in-vitro [4]. We therefore hypothesise that low 
haemoglobin levels leads to reactivation of KSHV through hypoxia. Increased reactivation may help 
spread the virus during initial infection. Alternately, hypoxia may enhance initial infection of cells, 
possibly through upregulation of the replication and transcription activator [14]. In this cross 
sectional study, we did not directly measure KSHV reactivation or KSHV viral load in blood or plasma, 
although antibody levels may be viewed as a surrogate marker for frequent reactivation. The 
connection between KSHV reactivation, hypoxia and anaemia requires further investigation.  
 
We showed that children infected with malaria are more likely to be KSHV seropositive. Additionally, 
the effect of anaemia and/or haemoglobin levels on KSHV prevalence and antibody levels reduced to 
about 50% after adjusting for malaria infection. Malaria causes anaemia, and in part the anaemia 
effect in children could be explained (confounded) by malaria infection. The consistent association 
between malaria infection and KSHV prevalence suggests malaria may be driving KSHV transmission 
in malaria endemic areas. This might imply that exposure to malaria significantly impacts on KSHV 
reactivation, which might also have long lasting effects. The mechanism through which malaria may 
reactivate KSHV requires further investigation.  
 
Conclusion  
Findings from this study suggest malaria infection as a risk factor for KSHV prevalence. Malaria 
associated anaemia is one mechanism that likely contributes to this association but cannot entirely 
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explain it. In KSHV and malaria endemic areas, a number of other parasite co-infections such as 
helminths, which cause anaemia and/or immunomodulation are common. The role of multiple 
parasitic infections and KSHV transmission and pathogenesis warrants further careful study.  
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Table 1: Risk factors for KSHV prevalence and antibody levels among adults 18 to 103 years.  
1A: Risk factors for KSHV prevalence  
Risk factor  KSHV prevalence Adjusted
 a
 Odds Ratio (95% CI) P value 
Age  1.01 (1.003, 1.02) 0.010 
Sex 
Males 
Females 
 
94% (1218/1297) 
89% (1653/1852) 
 
1 
0.61 (0.46, 0.80) 
 
 
0.001 
HIV and CD4 count status 
(-) CD4 count unknown 
(+) CD4 count > 500 
(+) CD4 count ч 500     
(+) CD4 count unknown 
 
92% (2615/2841) 
70% (32/46) 
90% (76/84) 
83% (146/175) 
 
1 
0.16 (0.10, 0.26) 
0.61 (0.16, 2.36) 
0.53 (0.29, 0.96) 
 
 
<0.0001 
0.451 
0.039 
Haemoglobin levels
b
   0.86 (0.77, 0.96) 0.006 
Anaemia
c
 
Normal 
Anaemic 
 
91% (2153/2370) 
92% (718/779) 
 
1 
1.25 (0.87, 1.79) 
 
 
0.229 
 
1B: Risk factors for anti-K8.1 and anti-ORF73 antibody levels  
 
Risk factor 
K8.1 ORF73 
Adjusted
a
 Coef.
 d
  
(95% CI) 
P value Adjusted
a
 Coef.
 d
 (95% 
CI) 
P value 
Age 0.004 (0.001, 0.007) 0.015 0.01 (0.007, 0.013) <0.0001 
Sex     
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Males 
Females 
Ref 
-0.25 (-0.35, -0.14) 
 
<0.0001 
 
-0.24 (-0.34, -0.14) 
 
<0.0001 
HIV and CD4 count status 
 (-) CD4 count unknown 
(+) CD4 count > 500 
(+) CD4 count ч 500    
(+) CD4 count unknown  
 
Ref 
-0.77 (-1.21, -0.33) 
-0.33 (-0.64, -0.02) 
-0.28 (-0.51, -0.06) 
 
 
0.001 
0.036 
0.014 
 
Ref 
-0.71 (-1.15, -0.29) 
-0.48 (-0.79, -0.17) 
-0.38 (-0.59, -0.16) 
 
 
0.001 
0.003 
0.001 
Haemoglobin levels
b
 -0.03 (-0.06, 0.01) 0.119   
Anaemia
c
 
Normal 
Anaemic 
 
Ref 
0.007 (-0.11, 0.13) 
 
 
0.910 
 
 
0.28 (0.16, 0.39) 
 
 
<0.0001 
 
1C: Age group specific association between anti-ORF73 antibody levels and haemoglobin levels  
 Age group Adjusted
a
 Coef.  
(95% CI) 
P value Interaction P 
value   
Haemoglobin levels
b
 18-24 
25-44 
45-103 
-0.09 (-0.16, -0.02) 
-0.08 (-0.12, -0.03) 
-0.17 (-0.21, -0.12) 
0.009 
0.001 
<0.0001 
 
 
0.007 
a
 adjusted for age, sex, HIV status and household socio-economic status, CI: confidence interval. Anti-K8.1 and anti-ORF73 
antibody levels (measured as optical density) were obtained from ELISA. KSHV seropositivity was defined as reactivity to 
either K8.1 or ORF73 antigens.
 b
haemoglobin levels were mean (13.7 g/dL) centred.  
c
haemoglobin levels were altitude 
adjusted and categorised into normal and anaemic following WHO guidelines.
 d
Coef.: regression coefficient, CI: confidence 
interval. Logistic regression, allowing for the survey design was used for statistical analysis of risk factors for KSHV 
prevalence. Linear regression with bootstrapped confidence intervals was used for statistical analysis of risk factors for 
antibody levels. Table 1C: Age group specific associations between ORF73 antibody levels and haemoglobin levels were 
reported due to interaction between age and Haemoglobin levels. CD4 counts were measured in cells/PL. 
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Table 2: Risk factors for KSHV prevalence and antibody levels among children aged 1 to 17 years. 
2A: Risk factors for KSHV prevalence 
  Adjusted
a
 Adjusted
b
 
Risk factor (n) KSHV prevalence OR (95% CI) P value OR (95% CI) P value 
Haemoglobin 
levels  (3199)
c 
  
0.89 (0.84, 0.93) 
 
<0.0001 
 
0.93 (0.88, 0.98) 
 
0.005 
Anaemia
d
 
Normal 
Anaemic 
 
44% (1143/2584) 
48% (294/615) 
 
1 
1.42 (1.18, 1.71) 
 
 
<0.0001 
 
 
1.23 (1.01, 1.49) 
 
 
0.037 
Malaria 
Negative  
Positive  
 
41% (1088/2630) 
61% (348/569) 
 
1 
2.22 (1.84, 2.69) 
 
 
<0.0001 
 
1 
2.13 (1.75, 2.58) 
 
 
<0.0001 
 
Age (4134) 
  
1.17 (1.15, 1.18) 
 
<0.0001 
 
1.18 (1.15, 1.21) 
 
<0.0001 
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Sex 
Boys  
Girls  
 
52% (1076/2061) 
50% (1041/2073) 
 
1 
0.93 (0.82, 1.07) 
 
 
0.27 
 
1 
0.94 (0.82, 1.07)  
 
 
0.33 
HIV 
Negative  
Positive  
 
53% (2030/3812) 
40% (19/48) 
 
1 
0.49 (0.25, 0.96) 
 
 
0.04 
 
1 
0.55 (0.30, 1.03) 
 
 
0.06 
 
2B: Risk factors for antibody levels  
 K8.1 ORF73 
 Adjusted
a
 Adjusted
b
 Adjusted
a
 Adjusted
b
 
Risk factor (n) Coef
e
. (95% CI) P value Coef. (95% CI) P value Coef. (95% CI) P value Coef. (95% CI) P value 
Malaria 
Negative (2630) 
Positive (569) 
 
ref 
0.27 (0.18, 0.38) 
 
 
<0.0001 
 
ref 
0.26 (0.16, 0.37) 
 
 
<0.0001 
 
ref 
0.30 (0.21, 0.38) 
 
 
<0.0001 
 
ref 
0.26 (0.18, 0.34) 
 
 
<0.0001 
Age (4134) 0.08 (0.07, 0.09) <0.0001 0.1 (0.08, 0.11) <0.0001 0.06 (0.05, 0.07) <0.0001 0.05 (0.04, 0.06) <0.0001 
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pt
 
 
 
Haemoglobin 
levels (3199)
c
 
-0.04 (-0.06, -0.01) 0.003 -0.02 (-0.05, 0.01) 0.2 -0.03 (-0.06, -0.01) 0.001 -0.02 (-0.04, 0.005) 0.13 
Anaemia
d
 
Normal 
Anaemic 
 
ref 
0.04 (-0.05, 0.13) 
 
 
0.414 
 
ref 
-0.02 (-0.12, 0.07) 
 
 
0.649 
 
ref 
0.12 (0.05, 0.19) 
 
 
0.001 
 
ref 
0.07 (-0.01, 0.14) 
 
 
0.073 
Sex 
Boys (2061) 
Girls (2073) 
 
ref 
-0.05 (-0.11, 0.02) 
 
 
0.17 
 
ref 
-0.01 (-0.09, 0.06) 
 
 
0.75 
 
ref 
0.01 (-0.04, 0.07) 
 
 
0.63 
 
ref 
-0.01 (-0.07, 0.05) 
 
 
0.66 
HIV 
Negative (3808) 
Positive (270) 
 
ref 
-0.24 (-0.56, 0.07) 
 
 
0.13 
 
ref 
-0.12 (-0.48, 0.24) 
 
 
0.5 
 
ref 
0.20 (-0.17, 0.57) 
 
 
0.29 
 
ref 
0.29 (-0.13, 0.72) 
 
 
0.18 
a
adjusted for age, sex and HIV status and 
b
adjusted for age, sex, HIV status, haemoglobin and malaria parasitaemia. Logistic regression, allowing for survey design was used for statistical 
analysis of risk factors and KSHV prevalence. OR: Odds Ratio, 
e
Coef.: regression coefficient CI: confidence Interval. ORF73 and K8.1 antibody levels (measured as optical density) were obtained 
from ELISA. KSHV prevalence defined as antibody reactivity to either K8.1 or ORF73 antigens. HIV status obtained using rapid diagnostic tests. Malaria parasitaemia determined using rapid 
diagnostic tests. 
c
haemoglobin levels were mean (13.0 g/dL) centred. 
d
haemoglobin levels were altitude adjusted and categorised into normal and anaemic following WHO guidelines. Linear 
regression with bootstrapped confidence interval used in the analysis of risk factors for KSHV antibody levels. 
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